Relenza (Zanamivir) News and Research

RSS
Relenza (zanamivir) is an anti-viral drug, for persons aged 7 years and older for the treatment of uncomplicated influenza illness. This product is approved to treat type A and B influenza, the two types most responsible for flu epidemics. Clinical studies showed that for the drug to be effective, patients needed to start treatment within two days of the onset of symptoms. The drug seemed to be less effective in patients whose symptoms weren't severe or didn't include a fever. Relenza is approved for preventive use, to decrease the risk of developing influenza illness, for persons aged 5 and older. Relenza is a powder that is inhaled twice a day for five days from a breath-activated plastic device called a Diskhaler for treatment of influenza. For preventive use to reduce the risk of getting influenza, Relenza is inhaled once daily for 10 to 28 days as prescribed by a healthcare provider.
Vietnamese researchers say bird flu already resisant to Tamiflu

Vietnamese researchers say bird flu already resisant to Tamiflu

George Bush needs more money to cope with bird flu

George Bush needs more money to cope with bird flu

Counterfeit Tamiflu drug a very real threat

Counterfeit Tamiflu drug a very real threat

Avian flu and planning for pandemic

Avian flu and planning for pandemic

As Europe panics, global co-operation urged in the fight against birdflu

As Europe panics, global co-operation urged in the fight against birdflu

Drug company donates bird flu vaccine to World Health Organization

Drug company donates bird flu vaccine to World Health Organization

Governments should consider stockpiling zanamivir (Relenza) for flu pandemics

Governments should consider stockpiling zanamivir (Relenza) for flu pandemics

Scientists have a plan to prevent bird flu pandemic

Scientists have a plan to prevent bird flu pandemic

Biota's potential damages claim against GlaxoSmithKline could be as high as $430 million

Biota's potential damages claim against GlaxoSmithKline could be as high as $430 million

Judge calls GlaxoSmithKline 'high-handed' over legal action from Biota

Judge calls GlaxoSmithKline 'high-handed' over legal action from Biota

State-of-the-art computer technology to tackle deadly diseases such as influenza

State-of-the-art computer technology to tackle deadly diseases such as influenza